Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV vs. ACTU, MDWD, CCCC, CGTX, TNYA, VTYX, TVGN, CRBU, NLTX, and DERMShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Actuate Therapeutics (ACTU), MediWound (MDWD), C4 Therapeutics (CCCC), Cognition Therapeutics (CGTX), Tenaya Therapeutics (TNYA), Ventyx Biosciences (VTYX), Tevogen Bio (TVGN), Caribou Biosciences (CRBU), Neoleukin Therapeutics (NLTX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Actuate Therapeutics MediWound C4 Therapeutics Cognition Therapeutics Tenaya Therapeutics Ventyx Biosciences Tevogen Bio Caribou Biosciences Neoleukin Therapeutics Journey Medical Actuate Therapeutics (NASDAQ:ACTU) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Do institutionals and insiders believe in ACTU or NBRV? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, ACTU or NBRV? Actuate Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/ANabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Does the media favor ACTU or NBRV? In the previous week, Actuate Therapeutics had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Actuate Therapeutics and 0 mentions for Nabriva Therapeutics. Actuate Therapeutics' average media sentiment score of 0.94 beat Nabriva Therapeutics' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Actuate Therapeutics Positive Nabriva Therapeutics Neutral Is ACTU or NBRV more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Actuate Therapeutics' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -281.83% Nabriva Therapeutics -148.11%-365.53%-135.81% Do analysts rate ACTU or NBRV? Actuate Therapeutics currently has a consensus price target of $20.33, indicating a potential upside of 133.18%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryActuate Therapeutics beats Nabriva Therapeutics on 9 of the 12 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$822.15M$5.76B$9.85BDividend YieldN/A4.84%6.71%4.51%P/E Ratio0.001.0759.1122.53Price / SalesN/A26.59547.00119.09Price / CashN/A19.5637.0558.92Price / BookN/A6.6410.916.06Net Income-$57.19M-$4.78M$3.29B$266.28M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ACTUActuate TherapeuticsN/A$8.70+3.1%$20.33+133.7%+7.4%$180.53MN/A0.0010MDWDMediWound1.5141 of 5 stars$16.60-0.6%$32.25+94.3%-2.8%$179.45M$20.22M-6.2980CCCCC4 Therapeutics2.1214 of 5 stars$2.51-3.5%$8.00+218.7%-57.4%$178.64M$35.58M-1.59150News CoverageAnalyst ForecastGap UpCGTXCognition Therapeutics1.1666 of 5 stars$2.42-0.4%$2.83+17.1%+273.8%$177.93MN/A-3.6120News CoverageTNYATenaya Therapeutics2.9553 of 5 stars$1.08-4.4%$6.25+478.7%-53.4%$176.01MN/A-1.13110Analyst ForecastVTYXVentyx Biosciences2.8039 of 5 stars$2.46+2.5%$7.50+204.9%+18.3%$175.42MN/A-1.4630News CoveragePositive NewsTVGNTevogen Bio3.5483 of 5 stars$0.89-2.2%$10.00+1,023.6%+89.0%$175.07MN/A0.003News CoverageAnalyst ForecastShort Interest ↑CRBUCaribou Biosciences2.5685 of 5 stars$1.88+0.5%$6.67+254.6%-4.5%$175.07M$9.12M-1.06100NLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-47.5%$173.68MN/A-5.9490News CoverageDERMJourney Medical1.8529 of 5 stars$7.12-1.2%$12.17+70.9%+45.1%$173.59M$56.13M-18.7490High Trading Volume Related Companies and Tools Related Companies ACTU Alternatives MDWD Alternatives CCCC Alternatives CGTX Alternatives TNYA Alternatives VTYX Alternatives TVGN Alternatives CRBU Alternatives NLTX Alternatives DERM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBRV Stock Alerts